Perspective Therapeutics' (CATX) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a buy rating for Perspective Therapeutics (CATX) with a price target of $10.00, indicating a potential upside of 203.95% from its current price.
• Perspective Therapeutics has received favorable ratings from multiple research firms, with a current consensus rating of Buy and a target price of $12.56.
• Shares of Perspective Therapeutics have risen 8.2%, and institutional investors own approximately 54.66% of the company's stock.

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 213.48% from the company's previous close.

Several other research analysts also recently issued reports on the stock. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Monday, September 15th. B. Riley reiterated a "buy" rating and set a $12.00 price target (up from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Finally, Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and upped their price target for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Stock Down 3.0%

NYSE CATX traded down $0.10 on Friday, hitting $3.19. 1,068,578 shares of the company's stock were exchanged, compared to its average volume of 925,891. The stock has a 50-day moving average of $3.69 and a 200-day moving average of $3.03. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $13.90.

Institutional Trading of Perspective Therapeutics

Hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the last quarter. Ground Swell Capital LLC bought a new stake in shares of Perspective Therapeutics during the 2nd quarter worth $56,000. Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the 2nd quarter worth $61,000. MetLife Investment Management LLC raised its position in Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company's stock worth $67,000 after purchasing an additional 9,082 shares during the period. Finally, Deutsche Bank AG raised its position in Perspective Therapeutics by 76.0% in the 4th quarter. Deutsche Bank AG now owns 46,579 shares of the company's stock worth $149,000 after purchasing an additional 20,120 shares during the period. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.